Immune regulation by the posttranslational modification O-GlcNAc

Current Signal Transduction Therapy

Volumn 5, Issue 1, 2010, Pages 41-48

  Pappa, Alexander ^a   Guerini, Danilo ^b  

^a MEDAC GMBH   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

B cell activation; O GlcNAc; O linked N acetylglucosamine; OGT; T cell activation

Indexed keywords

ACETYLGLUCOSAMINIDASE; N ACETYLGLUCOSAMINE; N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN KINASE;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME MODIFICATION; ENZYME REGULATION; ENZYME STRUCTURE; EUKARYOTIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 77951883683     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436210790226500     Document Type: Article

References (77)

1. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001; 291: 2376-8.
2. Zachara NE, Hart GW. O-GlcNAc modification: a nutritional sensor that modulates proteasome function. Trends Cell Biol 2004; 14: 218-21.
3. Hart GW, Greis KD, Dong LY, et al. O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Adv Exp Med Biol 1995; 376: 115-23.
4. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab 2008; 295: E17-28.
5. Nolte D, Muller U. Human O-GlcNAc transferase (OGT): genomic structure, analysis of splice variants, fine mapping in Xq13.1. Mamm Genome 2002; 13: 62-4.
6. Shafi R, Iyer SP, Ellies LG, et al. The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci USA 2000; 97: 5735-9.
7. Hanover JA, Lai Z, Lee G, Lubas WA, Sato SM. Elevated O-linked N-acetylglucosamine metabolism in pancreatic beta-cells. Arch Biochem Biophys 1999; 362: 38-45.
8. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem 1997; 272: 9308-15.
9. Lubas WA, Frank DW, Krause M, Hanover JA. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J Biol Chem 1997; 272: 9316-24.
10. Roos MD, Xie W, Su K, et al. Streptozotocin, an analog of N-acetylglucosamine, blocks the removal of O-GlcNAc from intracellular proteins. Proc Assoc Am Physicians 1998; 110: 422-32.
11. Hanover JA, Yu S, Lubas WB, et al. Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc transferase encoded by a single mammalian gene. Arch Biochem Biophys 2003; 409: 287-97.
12. Love DC, Kochan J, Cathey RL, Shin SH, Hanover JA. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J Cell Sci 2003; 116: 647-54.
13. Yang X, Ongusaha PP, Miles PD, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008; 451: 964-9.
14. Jinek M, Rehwinkel J, Lazarus BD, Izaurralde E, Hanover JA, Conti E. The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural similarities to importin alpha. Nat Struct Mol Biol 2004; 11: 1001-7.
15. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. Dynamic Oglycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem 2001; 276: 9838-45.
16. Wells L, Gao Y, Mahoney JA, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem 2002; 277: 1755-61.
17. Comtesse N, Maldener E, Meese E. Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-Nacetylglucosaminidase. Biochem Biophys Res Commun 2001; 283: 634-40.
18. Farook VS, Bogardus C, Prochazka M. Analysis of MGEA5 on 10q24.1-q24.3 encoding the beta-O-linked N-acetylglucosaminidase as a candidate gene for type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2002; 77: 189-93.
19. Toleman C, Paterson AJ, Whisenhunt TR, Kudlow JE. Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities. J Biol Chem 2004; 279: 53665-73.
20. Hurtado-Guerrero R, Dorfmueller HC, van Aalten DM. Molecular mechanisms of O-GlcNAcylation. Curr Opin Struct Biol 2008; 18: 551-7.
21. Cheng X, Cole RN, Zaia J, Hart GW. Alternative O-glycosylation/ O-phosphorylation of the murine estrogen receptor beta. Biochemistry 2000; 39: 11609-20.
22. Cheng X, Hart GW. Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta: posttranslational regulation of turnover and transactivation activity. J Biol Chem 2001; 276: 10570-5.
23. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 1995; 270: 18961-5.
24. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007; 446: 1017-22.
25. Kelly WG, Dahmus ME, Hart GW. RNA polymerase II is a glycoprotein. Modification of the COOH-terminal domain by OGlcNAc. J Biol Chem 1993; 268: 10416-24.
26. Medina V, Afonso JJ, Alvarez-Arguelles H, Hernandez C, Gonzalez F. Sodium butyrate inhibits carcinoma development in a 1,2- dimethylhydrazine-induced rat colon cancer. JPEN J Parenter Enteral Nutr 1998; 22: 14-7.
27. Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAcmodified proteins from the brain. Proc Natl Acad Sci USA 2004; 101: 13132-7.
28. Vosseller K, Trinidad JC, Chalkley RJ, et al. O-linked Nacetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5: 923-34.
29. Whitworth GE, Macauley MS, Stubbs KA, et al. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J Am Chem Soc 2007; 129: 635-44.
30. Haltiwanger RS, Grove K, Philipsberg GA. Modulation of Olinked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate. J Biol Chem 1998; 273: 3611-7.
31. Konrad RJ, Zhang F, Hale JE, Knierman MD, Becker GW, Kudlow JE. Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase. Biochem Biophys Res Commun 2002; 293: 207-12.
32. Gross BJ, Swoboda JG, Walker S. A strategy to discover inhibitors of O-linked glycosylation. J Am Chem Soc 2008; 130: 440-1.
33. Gross BJ, Kraybill BC, Walker S. Discovery of O-GlcNAc transferase inhibitors. J Am Chem Soc 2005; 127: 14588-9.
34. Dias WB, Hart GW. O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst 2007; 3: 766-72.
35. Hanover JA. Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J 2001; 15: 1865-76.
36. Yamamoto K, Tsuji T, Matsumoto I, Osawa T. Structural requirements for the binding of oligosaccharides and glycopeptides to immobilized wheat germ agglutinin. Biochemistry 1981; 20: 5894-9.
37. Cheung WD, Hart GW. AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J Biol Chem 2008; 283: 13009-20.
38. Viner RI, Zhang T, Second T, Zabrouskov V. Quantification of post-translationally modified peptides of bovine alpha-crystallin using tandem mass tags and electron transfer dissociation. J Proteomics 2009; 72: 874-85.
39. Vocadlo DJ, Hang HC, Kim EJ, Hanover JA, Bertozzi CR. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci USA 2003; 100: 9116-21.
40. Nandi A, Sprung R, Barma DK, Zhao Y, Kim SC, Falck JR. Global identification of O-GlcNAc-modified proteins. Anal Chem 2006; 78: 452-8.
41. Gurcel C, Vercoutter-Edouart AS, Fonbonne C, et al. Identification of new O-GlcNAc modified proteins using a click-chemistry-based tagging. Anal Bioanal Chem 2008; 390: 2089-97.
42. Clark PM, Dweck JF, Mason DE, et al. Direct in-gel fluorescence detection and cellular imaging of O-GlcNAc-modified proteins. J Am Chem Soc 2008; 130: 11576-7.
43. Holt GD, Snow CM, Senior A, Haltiwanger RS, Gerace L, Hart GW. Nuclear pore complex glycoproteins contain cytoplasmically disposed O-linked N-acetylglucosamine. J Cell Biol 1987; 104: 1157-64.
44. Park MK, D'Onofrio M, Willingham MC, Hanover JA. A monoclonal antibody against a family of nuclear pore proteins (nucleoporins): O-linked N-acetylglucosamine is part of the immunodeterminant. Proc Natl Acad Sci USA 1987; 84: 6462-6.
45. Snow CM, Senior A, Gerace L. Monoclonal antibodies identify a group of nuclear pore complex glycoproteins. J Cell Biol 1987; 104: 1143-56.
46. Comer FI, Vosseller K, Wells L, Accavitti MA, Hart GW. Characterization of a mouse monoclonal antibody specific for O-linked Nacetylglucosamine. Anal Biochem 2001; 293: 169-77.
47. Golks A, Tran TT, Goetschy JF, Guerini D. Requirement for Olinked N-acetylglucosaminyltransferase in lymphocytes activation. EMBO J 2007; 26: 4368-79.
48. Song M, Kim HS, Park JM, et al. O-GlcNAc transferase is activated by CaMKIV-dependent phosphorylation under potassium chlorideinduced depolarization in NG-108-15 cells. Cell Signal 2008; 20: 94-104.
49. Whelan SA, Lane MD, Hart GW. Regulation of the O-linked beta-N-acetylglucosamine transferase by insulin signaling. J Biol Chem 2008; 283: 21411-7.
50. Iyer SP, Akimoto Y, Hart GW. Identification and cloning of a novel family of coiled-coil domain proteins that interact with OGlcNAc transferase. J Biol Chem 2003; 278: 5399-409.
51. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW. Olinked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J Biol Chem 2008; 283: 33935-41.
52. Housley MP, Rodgers JT, Udeshi ND, et al. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 2008; 283: 16283-92.
53. Tallent MK, Varghis N, Skorobogatko Y, et al. In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J Biol Chem 2008; 284: 174-81.
54. Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem 2004; 279: 30133-42.
55. Jones SP, Zachara NE, Ngoh GA, et al. Cardioprotection by Nacetylglucosamine linkage to cellular proteins. Circulation 2008; 117: 1172-82.
56. Ohn T, Kedersha N, Hickman T, Tisdale S, Anderson P. A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. Nat Cell Biol 2008; 10: 1224-31.
57. Rengifo J, Gibson CJ, Winkler E, Collin T, Ehrlich BE. Regulation of the inositol 1,4,5-trisphosphate receptor type I by O-GlcNAc glycosylation. J Neurosci 2007; 27: 13813-21.
58. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE. OGlcNAc modification is an endogenous inhibitor of the proteasome. Cell 2003; 115: 715-25.
59. Guinez C, Mir AM, Dehennaut V, et al. Protein ubiquitination is modulated by O-GlcNAc glycosylation. FASEB J 2008; 22: 2901-11.
60. Yang WH, Kim JE, Nam HW, et al. Modification of p53 with Olinked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 2006; 8: 1074-83.
61. Slawson C, Zachara NE, Vosseller K, Cheung WD, Lane MD, Hart GW. Perturbations in O-linked beta-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis. J Biol Chem 2005; 280: 32944-56.
62. Izawa I, Inagaki M. Regulatory mechanisms and functions of intermediate filaments: a study using site- and phosphorylation statespecific antibodies. Cancer Sci 2006; 97: 167-74.
63. Kearse KP, Hart GW. Lymphocyte activation induces rapid changes in nuclear and cytoplasmic glycoproteins. Proc Natl Acad Sci USA 1991; 88: 1701-5.
64. James LR, Tang D, Ingram A, et al. Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes 2002; 51: 1146-56.
65. Golks A, Guerini D. The O-linked N-acetylglucosamine modification in cellular signalling and the immune system. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 748-53.
66. Yang WH, Park SY, Nam HW, et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci USA 2008; 105: 17345-50.
67. O'Donnell N, Zachara NE, Hart GW, Marth JD. Ogt-dependent Xchromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol 2004; 24: 1680-90.
68. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. Olinkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci USA 2001; 98: 6611-6.
69. Roos MD, Su K, Baker JR, Kudlow JE. O-glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol 1997; 17: 6472-80.
70. Jochmann R, Thurau M, Jung S, et al. O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol 2009; 83: 3704-18.
71. Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by O-linked N-acetylglucosamine. J Biol Chem 2003; 278: 10022-7.
72. Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 2002; 99: 5313-8.
73. Grigorian A, Lee SU, Tian W, et al. Control of T Cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J Biol Chem 2007; 282: 20027-35.
74. Xing D, Feng W, Not LG, et al. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol 2008; 295: H335-42.
75. Kneass ZT, Marchase RB. Neutrophils exhibit rapid agonistinduced increases in protein-associated O-GlcNAc. J Biol Chem 2004; 279: 45759-65.
76. Kneass ZT, Marchase RB. Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils. J Biol Chem 2005; 280: 14579-85.
77. Rexach JE, Clark PM, Hsieh-Wilson LC. Chemical approaches to understanding O-GlcNAc glycosylation in the brain. Nat Chem Biol 2008; 4: 97-106.